Background: Resveratrol is a polyphenol that has gained momentum in therapeutics in the
last few years.
Objective: In this study, we hypothesised that resveratrol could act prophylactically and/or treat inflammatory
lesions of the oral cavity after being delivered by two different formulations of buccal mucoadhesive
tablets (F1 and F2, which differed in terms of viscosity agents used).
Methods: This hypothesis was assessed through permeation studies, to verify diffusion of the drug
through the buccal mucosa using a porcine model to predict human in vivo behaviour.
Results: F2 (tablet with less viscosity agent) presented better permeation than F1, but the amount of
drug that crossed the mucosa was still low compared to the amount retained within it (35.90 µg found in
the receptor medium and 15.63 mg quantified within the mucosa).
Conclusion: This accounted for a local effect rather than a systemic one, which is desirable for local
processes, such as oral mucositis, lichen planus, erythema multiforme, nicotinic stomatitis, recurrent
aphthous stomatitis, among others. In this sense, resveratrol-loaded mucoadhesive tablets appear to be a
prominent alternative to prevent and/or cure inflammatory lesions of the oral cavity.